Linezolid for drug-susceptible tuberculosis.

Ahmed, Saiam; Moore, David Aj; Nimmo, Camus; Nunn, Andrew J; Yates, Tom A

Ahmed, Saiam; Moore, David Aj; Nimmo, Camus; Nunn, Andrew J; Yates, Tom A.

Afiliación

Ahmed S; Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London (UCL), London WC1V 6LJ, UK. Electronic address: saiam.ahmed@ucl.ac.uk.
Moore DA; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Nimmo C; Division of Infection and Immunity, UCL, London, UK.
Nunn AJ; Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London (UCL), London WC1V 6LJ, UK.
Yates TA; Section of Infectious Diseases and Immunity, Imperial College London, London, UK.

Lancet Infect Dis ; 19(4): 357, 2019 04.

Article en En | MEDLINE | ID: mdl-30938294

Asunto(s)

Tuberculosis Pulmonar; Tuberculosis; Etambutol; Humanos; Linezolid; Estudios Prospectivos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tuberculosis / Tuberculosis Pulmonar Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Lancet Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google